Abstract
Alzheimer’s disease (AD) is biochemically characterized by the occurrence of extracellular deposits of amyloid beta peptide (Aβ) and intracellular deposits of the hyperphosphorylated tau protein, which are causally related to the pathological hallmarks senile plaques and neurofibrillary tangles. Monoamine oxidase B (MAO-B) activity, involved in the oxidation of biogenic monoamines, is particularly high around the senile plaques and increased in AD patients in middle to late clinical stages of the disease. Selegiline is a selective and irreversible MAO-B inhibitor and, although clinical trials already shown the beneficial effect of selegiline on cognition of AD patients, its mechanism of action remains to be elucidated. Therefore, we first investigated whether selegiline reverses the impairment of object recognition memory induced by Aβ25–35 in mice, an established model of AD. In addition, we investigated whether selegiline alters MAO-B and MAO-A activities in the hippocampus, perirhinal and remaining cerebral cortices of Aβ25–35-injected male mice. Acute (1 and 10 mg/kg, p.o., immediately post-training) and subchronic (10 mg/kg, p.o., seven days after Aβ25–35 injection and immediately post-training) administration of selegiline reversed the cognitive impairment induced by Aβ25–35 (3 nmol, i.c.v.). Acute administration of selegiline (1 mg/kg, p.o.) in combination with Aβ25–35 (3 nmol) decreased MAO-B activity in the perirhinal and remaining cerebral cortices. Acute administration of selegiline (10 mg/kg, p.o.) decreased MAO-B activity in hippocampus, perirhinal and remaining cerebral cortices, regardless of Aβ25–35 or Aβ35–25 treatment. MAO-A activity was not altered by selegiline or Aβ25–35. In summary, the current findings further support a role for cortical monoaminergic transmission in the cognitive deficits observed in AD.
Similar content being viewed by others
References
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 9 (1):63–75 e62
Comas-Herrera A, Northey S, Wittenberg R, Knapp M, Bhattacharyya S, Burns A (2011) Future costs of dementia-related long-term care: exploring future scenarios. Int Psychogeriatr 23(1):20–30
Desai AK, Grossberg GT (2005) Diagnosis and treatment of Alzheimer’s disease. Neurology 64(12 Suppl 3):S34–S39
Doody RS (2005) Refining treatment guidelines in Alzheimer’s disease. Geriatr Suppl: 14–20
Fan LY, Chiu MJ (2010) Pharmacological treatment for Alzheimer’s disease: current approaches and future strategies. Acta Neurol Taiwan 19(4):228–245
Jenner P (2004) Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson’s disease. Neurology 63(7 Suppl 2):S13–S22
Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM (2004) Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 19(4):426–432
Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ (2006) Practice parameter: treatment of parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66(7):983–995
Youdim MB, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7(4):295–309
Reinikainen KJ, Soininen H, Riekkinen PJ (1990) Neurotransmitter changes in Alzheimer’s disease: implications to diagnostics and therapy. J Neurosci Res 27(4):576–586
Sparks DL, Woeltz VM, Markesbery WR (1991) Alterations in brain monoamine oxidase activity in aging, Alzheimer’s disease, and pick’s disease. Arch Neurol 48(7):718–721
Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, Loffler J, Richards JG (1994) Increased monoamine oxidase B activity in plaque-associated astrocytes of alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62(1):15–30
Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. the Alzheimer’s disease cooperative study. N Engl J Med 336(17):1216–1222
Thomas T (2000) Monoamine oxidase-B inhibitors in the treatment of Alzheimer’s disease. Neurobiol Aging 21(2):343–348
Wilcock GK, Birks J, Whitehead A, Evans SJ (2002) The effect of selegiline in the treatment of people with Alzheimer’s disease: a meta-analysis of published trials. Int J Geriatr Psychiatry 17(2):175–183
Haley TJ, McCormick WG (1957) Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12(1):12–15
Antunes M, Biala G The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process 13 (2):93–110
Wang D, Noda Y, Zhou Y, Mouri A, Mizoguchi H, Nitta A, Chen W, Nabeshima T (2007) The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology 32(6):1261–1271
Nagai T, Yamada K, Kim HC, Kim YS, Noda Y, Imura A, Nabeshima Y, Nabeshima T (2003) Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. Faseb J 17(1):50–52
Kamei H, Nagai T, Nakano H, Togan Y, Takayanagi M, Takahashi K, Kobayashi K, Yoshida S, Maeda K, Takuma K, Nabeshima T, Yamada K (2006) Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice. Biol Psychiatry 59(1):75–84
Roozendaal B, Castello NA, Vedana G, Barsegyan A, McGaugh JL (2008) Noradrenergic activation of the basolateral amygdala modulates consolidation of object recognition memory. Neurobiol Learn Mem 90(3):576–579
Matsumoto T, Suzuki O, Furuta T, Asai M, Kurokawa Y, Nimura Y, Katsumata Y, Takahashi I (1985) A sensitive fluorometric assay for serum monoamine oxidase with kynuramine as substrate. Clin Biochem 18(2):126–129
Sant’ Anna Gda S, Machado P, Sauzem PD, Rosa FA, Rubin MA, Ferreira J, Bonacorso HG, Zanatta N, Martins MA (2009) Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett 19(2):546–549
Villarinho JG, Oliveira SM, Silva CR, Cabreira TN, Ferreira J (2012) Involvement of monoamine oxidase B on models of postoperative and neuropathic pain in mice. Eur J Pharmacol 690(1–3):107–114
Tsunekawa H, Noda Y, Mouri A, Yoneda F, Nabeshima T (2008) Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25–35). Behav Brain Res 190(2):224–232
Takahata K, Minami A, Kusumoto H, Shimazu S, Yoneda F (2005) Effects of selegiline alone or with donepezil on memory impairment in rats. Eur J Pharmacol 518(2–3):140–144
de Lima MN, Laranja DC, Caldana F, Bromberg E, Roesler R, Schroder N (2005) Reversal of age-related deficits in object recognition memory in rats with l-deprenyl. Exp Gerontol 40(6):506–511
Filip V, Kolibas E (1999) Selegiline in the treatment of Alzheimer’s disease: a long-term randomized placebo-controlled trial. Czech and slovak senile dementia of alzheimer type study group. J Psychiatry Neurosci 24(3):234–243
Braak H, Braak E (1991) Neuropathological stageing of alzheimer-related changes. Acta Neuropathol 82(4):239–259
Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, Ghozali F, Fallet-Bianco C, Pasquier F, Lebert F, Petit H, Di Menza C (1999) The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease. Neurology 52(6):1158–1165
Bevilaqua L, Ardenghi P, Schroder N, Bromberg E, Schmitz PK, Schaeffer E, Quevedo J, Bianchin M, Walz R, Medina JH, Izquierdo I (1997) Drugs acting upon the cyclic adenosine monophosphate/protein kinase a signalling pathway modulate memory consolidation when given late after training into rat hippocampus but not amygdala. Behav Pharmacol 8(4):331–338
Bach ME, Barad M, Son H, Zhuo M, Lu YF, Shih R, Mansuy I, Hawkins RD, Kandel ER (1999) Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci U S A 96(9):5280–5285
Ebadi M, Sharma S, Shavali S, El Refaey H (2002) Neuroprotective actions of selegiline. J Neurosci Res 67(3):285–289
Schulzer M, Mak E, Calne DB (1992) The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 32(6):795–798
Paterson IA, Zhang D, Warrington RC, Boulton AA (1998) R-deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium. J Neurochem 70(2):515–523
Kiray M, Uysal N, Sonmez A, Acikgoz O, Gonenc S (2004) Positive effects of deprenyl and estradiol on spatial memory and oxidant stress in aged female rat brains. Neurosci Lett 354(3):225–228
Thomas T, McLendon C, Thomas G (1998) L-deprenyl: nitric oxide production and dilation of cerebral blood vessels. NeuroReport 9(11):2595–2600
Zeng YC, Bongrani S, Bronzetti E, Cadel S, Ricci A, Valsecchi B, Amenta F (1995) Effect of long-term treatment with L-deprenyl on the age-dependent microanatomical changes in the rat hippocampus. Mech Ageing Dev 79(2–3):169–185
Magyar K, Haberle D (1999) Neuroprotective and neuronal rescue effects of selegiline: review. Neurobiology (Bp) 7(2):175–190
Pitsikas N, Rigamonti AE, Cella SG, Sakellaridis N, Muller EE (2005) The nitric oxide donor molsidomine antagonizes age-related memory deficits in the rat. Neurobiol Aging 26(2):259–264
Fin C, da Cunha C, Bromberg E, Schmitz PK, Bianchin M, Medina JH, Izquierdo I (1995) Experiments suggesting a role for nitric oxide in the hippocampus in memory processes. Neurobiol Learn Mem 63(2):113–115
Liu P, Smith PF, Appleton I, Darlington CL, Bilkey DK (2004) Potential involvement of NOS and arginase in age-related behavioural impairments. Exp Gerontol 39(8):1207–1222
Acknowledgments
This study was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) (Brazil).
Conflict of interest
The authors have declared that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Andréia M. Pazini and Guilherme M. Gomes have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Pazini, A.M., Gomes, G.M., Villarinho, J.G. et al. Selegiline Reverses Aβ25–35-Induced Cognitive Deficit in Male Mice. Neurochem Res 38, 2287–2294 (2013). https://doi.org/10.1007/s11064-013-1137-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-013-1137-6